Delay in bringing upgraded production equipment online in the injection needle business
First written in FY2019-Q3. 2 of 3 entries say "Mitigated", first in FY2020-Q1. Latest entry: FY2020-Q3.
No other company in this theme has enough history to compare yet.
- FY2020-Q3MitigatedAnnual report
「The dental business, where sales of dental materials expanded, and the injection needle business, which modernized its production facilities, both progressed steadily. The new consolidation effect from M&A conducted in the previous consolidated fiscal year also contributed.」
The hypodermic needle business has continued to perform steadily even after the modernization of its production facilities, indicating that the impact of the previously identified risk of start-up delays continues to diminish. - FY2020-Q1MitigatedAnnual report
「In the everyday healthcare field, the home healthcare and hygiene materials businesses were roughly in line with the same period of the previous year, while the dental business, where sales of dental-related materials expanded, and the hypodermic needle business performed steadily.」
Regarding the production equipment start-up delay in the hypodermic needle business described in the previous filing, the current filing states that the business performed steadily, indicating that the impact has diminished. - FY2019-Q3MaterialisedAnnual report
「In the dental business, sales of dental-related materials remained strong, but distribution and other costs increased in the mail-order business for dental clinics.」
Although orders recovered in the hypodermic needle business, the filing describes the impact of delays in starting up the upgraded production equipment.